Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth

Financial Highlights for Interim Results ended 30 June 2025 Revenue reached RMB831.9 million Gross profit amounted to RMB339.4 million Gross profit margin was 40.8%, an increase of 6.3 percentage point Net profit amounted to RMB148.6 million, increased by 3.1% YoY Adjusted non-IFRS net...